Norlase Leaf laser receives CE mark approval

Article

Distribution to begin in the European Union.

Norlase has been granted the European CE mark for its Leaf laser, following a 510(l)-market clearance by the US Food and Drug Administration (FDA) and ISO 13485:2016 certification. This approval will allow the company to market and distribute its fiberglass, green laser for the treatment of retina and glaucoma diseases in the European Union and other countries that recognize the European standard.

Related: CooperVision produces hand sanitizer at manufacturing sites

“This marks another significant milestone as we continue our mission to improve practice efficiency and workflow for ophthalmologists and equip them with the tools to provide quality eye care for patients worldwide,” said Oliver Hvidt, Norlase president, in a statement.

The Leaf laser photocoagulator allows ophthalmologists to perform laser therapy with minimal set-up time and physical space because it attaches to an existing slit lamp. It connects to a wireless tablet as its user interface and offers voice control features. Physicians can operate it touch-free.

Related: Allergan receives FDA complete response letter for wet AMD therapy

Recent Videos
Abby Gillogly Harsch, OD, FAAO, FSLS, shares a specific complex case of scleral lens fitting that she presented on at this year's GSLS.
Sherrol Reynolds, OD, FAAO, values the ophthalmic-optometric collaboration on display at the summit, running from February 14-17, 2025 in San Juan, Puerto Rico.
Katie Rachon, OD, FAAO, Dipl ABO, shares her excitement for the upcoming conference and what it means for an optometrist's toolbox.
EnVision Summit Cochair Cecelia Koetting, OD, FAAO, Dipl ABO, says that attendees should get ready for more discussion-based panels at this year's conference.
From contact lens dropout to addressing diabetic retinopathy in rural communities, optometrists choose an area of eye care research that they would expand, given the appropriate resources.
Bonnie An Henderson in an interview for the EnVision Summit
From new treatments on the horizon for macular degeneration to strengthening comanagement ties, optometrists cite a lot to be excited about in the coming year.
© 2025 MJH Life Sciences

All rights reserved.